Effect of emodin combined with survivin shRNA on proliferation of human breast cancer MCF-7 cells

doi:10.3877/cma.j.issn.1674-0807.2019.03.002

Abstract

Abstract:

Objective

To investigate the effect of emodin combined with survivin shRNA on the proliferation of human breast cancer MCF-7 cells.

Methods

The human breast cancer MCF-7 cells were cultured and treated with different concentrations of emodin (0, 10, 20, 40, 80 μmol/L). The effect of emodin on the proliferation of human breast cancer MCF-7 cells was determined by MTT assay to select suitable concentration (40 μmol/L) for subsequent experiments. Then the human breast cancer MCF-7 cells were divided into five groups: blank control group, negative control group (NC shRNA group, treated by empty plasmid), emodin treatment group (treated by 40 μmol/L emodin), survivin shRNA treatment group (transfected with survivin shRNA plasmid) and combined treatment group (treated by 40 μmol/L emodin plus survivin shRNA). The proliferation (optical density) and apoptosis of human breast cancer MCF-7 cells in each group were analyzed by MTT assay and flow cytometry, respectively. Because the result of MTT assay showed no significant difference in cell proliferation activity between blank control group and negative control group, no negative control group was established for the flow cytometry. Survivin mRNA and protein expressions were also assessed using real-time PCR and Western blot analysis, respectively. The apoptosis rate and survivin mRNA and protein expression were compared among multiple groups by one-way analysis of variance. The optical density was compared by repeated measurement analysis of variance. Pairwise comparison was performed using LSD method.

Results

The result of MTT assay showed that after 24, 48, and 72 h treatment of emodin at different concentrations (0, 10, 20, 40, 80 μmol/L), the optical density of each group was significantly different (F=1 873.565, P<0.001). The inhibitory rate of 40 μmol/L emodin on cell proliferation was (53.6±1.2)% (>50.0%), so this concentration of emodin was used for the following experiments. After the cells were treated with differeht methods for 24, 48, and 72 h, the optical density presented a significant difference among blank control group, negative control group, emodin treatment group, survivin shRNA treatment group and combined treatment group (F=1 686.953, P<0.001), the optical density was significantly different at different time points (F=288.790, P<0.001), and there was an interaction between grouping and time points (F=67.916, P<0.001). The results of flow cytometry showed that the apoptosis rate was (0.57±0.10)%, (5.96±0.56)%, (9.00±0.73)% and (18.33±0.98)% in blank control group, emodin treatment group, survivin shRNA treatment group and combined treatment group, respectively, indicating a significant difference (F=114.848, P<0.001). The apoptosis rate of emodin treatment group was significantly higher than that of blank control group (P<0.001); the apoptosis rate of combined treatment group was significantly higher than that of any other group (P<0.001). The results of real-time PCR showed that survivin mRNA expression was 1.000±0.000, 0.968±0.033, 0.774±0.049, 0.483±0.026 and 0.364±0.012 in blank control group, negative control group, emodin treatment group, survivin shRNA treatment group and combined treatment group, respectively, indicating a significant difference (F=284.199, P<0.001). Pairwise comparison showed that survivin mRNA expression in combined treatment group was significantly lower than that in emodin treatment group (P<0.001) or survivin shRNA treatment group (P=0.001). Western blot analysis showed that survivin protein expression was 1.000±0.000, 0.987±0.031, 0.696±0.050, 0.534±0.065 and 0.312±0.039 in blank control group, negative control group, emodin treatment group, survivin shRNA treatment group and combined treatment group, respectively, indicating a significant difference (F=142.311, P<0.001). Pairwise comparison showed that survivin protein expression in combined treatment group was significantly lower than that in emodin treatment group or survivin shRNA treatment group (both P<0.001).

Conclusion

The combination of emodin and survivin shRNA can inhibit the proliferation of human breast cancer MCF-7 cells.

Key words: Breast neoplasms, Emodin, Survivin, shRNA, Cell proliferation

Cong Zu, Guangyuan Qin, Xinyu Zheng. Effect of emodin combined with survivin shRNA on proliferation of human breast cancer MCF-7 cells[J]. Chinese Journal of Breast Disease(Electronic Edition), 2019, 13(03): 137-144.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2019.03.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2019/V13/I03/137

Figures/Tables 6

References 25

[1]	薛静，王浩. 乳腺癌免疫治疗的研究进展[J/CD]. 中华乳腺病杂志(电子版)，2018, 12(1):43-49.
[2]	李明卉，夏添松，王水. 乳腺癌常用化疗药物的作用机制及血液学不良反应的研究进展[J/CD]. 中华乳腺病杂志(电子版)，2017, 11(3):186-190.
[3]	Khongkow P, Gomes AR, Gong C, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance [J]. Oncogene，2016, 35(8):990-1002.
[4]	马哿，王佳，夏添松，等. 淋巴细胞趋化因子对乳腺癌MCF-7细胞的表柔比星药物敏感性及侵袭转移能力的影响[J/CD]. 中华乳腺病杂志(电子版)，2017, 11(6):354-360.
[5]	Yang F, Yuan P, Hao YQ, et al. Emodin enhances osteogenesis and inhibits adipogenesis[J]. BMC Complement Altern Med，2014, 14: 74.
[6]	Xing JY, Song GP, Deng JP, et al. Antitumor effects and mechanism of novel emodin rhamnoside derivatives against human cancer cells in vitro[J]. PLoS One，2015, 10(12):e0144781.
[7]	Thacker PC, Karunagaran D. Curcumin and emodin down-regulate TGF-β signaling pathway in human cervical cancer cells[J]. PLoS One，2015, 10(3):e0120045.
[8]	Li XX, Dong Y, Wang W, et al. Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma[J]. Stem Cells Dev，2013, 22(4): 554-566.
[9]	Pan FP, Zhou HK, Bu HQ, et al. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK[J]. Oncol Rep，2016, 35(4):1941-1949.
[10]	Garg H, Suri P, Gupta JC, et al. Survivin：a unique target for tumor therapy[J]. Cancer Cell Int，2016, 16: 49.
[11]	Khan Z, Khan AA, Yadav H, et al. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma[J]. Cell Mol Biol Lett，2017, 22: 8.
[12]	刘翠翠，王光学，赵倩，等. 长链非编码RNA调控乳腺癌增殖、转移、耐药性及乳腺癌干细胞[J/CD]. 中华乳腺病杂志(电子版)，2016, 10(5):310-315.
[13]	孟智超，李淑玲，肖建英．大黄素抑制卵巢癌SKOV3细胞增殖和抑制survivin及XIAP的蛋白表达[J]. 基础医学与临床，2014, 34(9): 1255-1259.
[14]	薛晖，李天人，贺安宁，等. Survivin shRNA与大黄素联合应用抗人卵巢癌细胞株增殖的实验研究[J]. 现代肿瘤医学，2014, 22(11):2557-2561.
[15]	Liu W, Tang L, Ye L, et al. Species and gender differences affect the metabolism of emodin via glucuronidation[J]. AAPS J，2010, 12(3):424-436.
[16]	Huang FJ, Hsuuw YD, Chan WH. Characterization of apoptosis induced by emodin and related regulatory mechanisms in human neuroblastoma cells[J]. Int J Mol Sci，2013, 14(10):20 139-20 156.
[17]	廖子君，宋永春，陈晓泉，等．大黄素对人肺腺癌A-549细胞增殖周期影响的实验研究[J]. 中华肿瘤防治杂志，2007, 14(5):342-344.
[18]	Zu C, Zhang MD, Xue H, et al. Emodin induces apoptosis of human breast cancer cells by modulating the expression of apoptosis-related genes[J]. Oncol Lett，2015, 10(5): 2919-2924.
[19]	周颉，傅建民，石剑，等．大黄素逆转乳腺癌细胞多药耐药及其对ERCC1蛋白表达的影响[J]. 中华肿瘤防治杂志，2010, 17(1):27-29.
[20]	焦冰洋，王闯，刘悦，等．大黄素通过下调Prx V蛋白水平诱导AGS胃癌细胞凋亡[J]. 黑龙江八一农垦大学学报，2018, 30(1):24-28.
[21]	Mattheolabakis G, Ling DD, Ahmad G, et al. Enhanced anti-tumor efficacy of lipid-modified platinum derivatives in combination with surviving silencing siRNA in resistant non-small cell lung cancer[J]. Pharm Res，2016, 33(12): 2943-2953.
[22]	He XJ, Zhang Q, Ma LP, et al. Aberrant alternative polyadenylation is responsible for survivin up-regulation in ovarian cancer[J]. Chin Med J (Engl)，2016, 129(10): 1140-1146.
[23]	Véquaud E, Desplanques G, Jézéquel P, et al. survivin contributes to DNA repair by homologous recombination in breast cancer cells[J]. Breast Cancer Res Treat, 2016，155(1): 53-63.
[24]	Chen X, Duan N, Zhang CG, et al. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies[J]. J Cancer，2016, 7(3):314-323.
[25]	Kelly RJ, Lopez-Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin [J]. Mol Cancer，2011, 10:35.

组别	实验次数	24 h	48 h	72 h
0 μmol/L^a	3	0.392±0.009	0.584±0.007	0.606±0.003
10 μmol/L	3	0.371±0.012	0.541±0.006	0.528±0.004
20 μmol/L	3	0.345±0.009	0.497±0.004	0.429±0.005
40 μmol/L^b	3	0.269±0.023	0.313±0.003	0.287±0.007
80 μmol/L	3	0.239±0.015	0.189±0.003	0.188±0.004

组别	实验次数	24 h	48 h	72 h
0 μmol/L^a	3	0.392±0.009	0.584±0.007	0.606±0.003
10 μmol/L	3	0.371±0.012	0.541±0.006	0.528±0.004
20 μmol/L	3	0.345±0.009	0.497±0.004	0.429±0.005
40 μmol/L^b	3	0.269±0.023	0.313±0.003	0.287±0.007
80 μmol/L	3	0.239±0.015	0.189±0.003	0.188±0.004

组别	实验次数	24 h	48 h	72 h
空白对照组	3	0.392±0.009	0.584±0.007	0.606±0.003
阴性对照组(NC shRNA组)	3	0.375±0.011	0.559±0.002	0.567±0.025
大黄素处理组^a	3	0.269±0.023	0.313±0.003	0.287±0.007
survivin shRNA处理组^a	3	0.213±0.024	0.258±0.003	0.249±0.006
联合处理组^b	3	0.159±0.004	0.168±0.002	0.136±0.006

组别	实验次数	24 h	48 h	72 h
空白对照组	3	0.392±0.009	0.584±0.007	0.606±0.003
阴性对照组(NC shRNA组)	3	0.375±0.011	0.559±0.002	0.567±0.025
大黄素处理组^a	3	0.269±0.023	0.313±0.003	0.287±0.007
survivin shRNA处理组^a	3	0.213±0.024	0.258±0.003	0.249±0.006
联合处理组^b	3	0.159±0.004	0.168±0.002	0.136±0.006

组别	实验次数	survivin mRNA	survivin蛋白
空白对照组	3	1.000±0.000	1.000±0.000
阴性对照组(NC shRNA组)	3	0.968±0.033	0.987±0.031
大黄素处理组	3	0.774±0.049^a	0.696±0.050^a
survivin shRNA处理组	3	0.483±0.026^a	0.534±0.065^a
联合处理组	3	0.364±0.012^b	0.312±0.039^c
F值	?	284.199	142.311
P值	?	<0.001	<0.001

Please choose a citation manager

Content to export